國藥控股(01099.HK)上半年歸母淨利35.83億元 同比增長23.73%
格隆匯8月23日丨國藥控股(01099.HK)發佈2021年中期業績公吿,報吿期間,實現收入人民幣2491.20億元,同比增長22.26%;毛利人民幣205.87億元,同比增長19.4%;歸屬於母公司持有者溢利人民幣35.83億元,同比增長23.73%;基本及攤薄每股盈利人民幣1.15元。
公吿表示,2021年是集團落實“十四五”發展戰略規劃的元年。報吿期內,集團在董事會和管理層的帶領下,克服疫情造成的負面影響以及行業毛利承壓等複雜多變的挑戰,積極承接疫苗配送及營銷推廣等全新服務需求,在確保各項業務穩定增長的基礎上,充分履行了醫藥行業央企的責任擔當,鞏固了核心主業的領先地位。同時,集團深入推進數字化轉型,統籌推進業務發展和模式轉型等各項重點工作,圓滿實現了上半年各項業務發展目標。從2021年上半年的整體財務表現來看,集團營業收入、淨利潤等業績指標同比增長較快,費用率等成本指標持續下降,應收賬款、存貨的週轉天數以及整體營運週期等效率指標顯著提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.